CATAPRES dosage and administration: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Pratik Bahekar (talk | contribs)
nocaptcha
3,696 edits
No edit summary
Pratik Bahekar (talk | contribs)
nocaptcha
3,696 edits
No edit summary
Line 3: Line 3:
{{CMG}}; {{AE}} {{PB}}
{{CMG}}; {{AE}} {{PB}}


'''''For patient information, click [[Ergotamine (patient information)|here]]'''''.
'''''For patient information about Ergotamine, click [[Ergotamine (patient information)|here]]'''''


==Dosage and Administration==


===Adults===


The dose of Catapres® (Ergotamine hydrochloride, USP) tablets must be adjusted according to the patient's individual blood pressure response. The following is a general guide to its administration.


===Initial Dose===
<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ERGOMAR (ERGOTAMINE TARTRATE) TABLET, ORALLY DISINTEGRATING [ROSEDALE THERAPEUTICS] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1bfd4827-5123-4dbb-8f94-7b097f5bfd5c | publisher =  | date =  | accessdate = 11 February 2014 }}</ref>
 
0.1 mg tablet twice daily (morning and bedtime). Elderly patients may benefit from a lower initial dose.
 
===Maintenance Dose===
 
Further increments of 0.1 mg per day may be made at weekly intervals if necessary until the desired response is achieved. Taking the larger portion of the oral daily dose at bedtime may minimize transient adjustment effects of dry mouth and drowsiness. The therapeutic doses most commonly employed have ranged from 0.2 mg to 0.6 mg per day given in divided doses. Studies have indicated that 2.4 mg is the maximum effective daily dose, but doses as high as this have rarely been employed.
 
===Renal Impairment===
 
Patients with renal impairment may benefit from a lower initial dose. Patients should be carefully monitored. Since only a minimal amount of Ergotamine is removed during routine hemodialysis, there is no need to give supplemental Ergotamine following dialysis.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = CATAPRES (Ergotamine HYDROCHLORIDE) TABLET [BOEHRINGER INGELHEIM PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d7f569dc-6bed-42dc-9bec-940a9e6b090d | publisher =  | date =  | accessdate = 5 February 2014 }}</ref>


==References==
==References==
Line 27: Line 14:
{{Reflist|2}}
{{Reflist|2}}


{{Antimigraine preparations}}
[[Category:Cardiovascular Drugs]]
 
[[Category:Drugs]]
[[Category:Drugs]]

Revision as of 02:01, 11 February 2014

Ergotamine
ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Medihaler ergotamine (ergotamine tartrate) aerosol, metered® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Medihaler ergotamine (ergotamine tartrate) aerosol, metered
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

For patient information about Ergotamine, click here



[1]

References

  1. ↑ "ERGOMAR (ERGOTAMINE TARTRATE) TABLET, ORALLY DISINTEGRATING [ROSEDALE THERAPEUTICS]". Retrieved 11 February 2014.
Retrieved from "https://www.wikidoc.org/index.php?title=CATAPRES_dosage_and_administration&oldid=941747"